vs
凯勒威廉姆斯（CTO）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是凯勒威廉姆斯的1.7倍（$69.8M vs $41.2M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 15.1%，领先369.0%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 15.0%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 19.5%）
凯勒威廉姆斯地产是一家美国科技企业及跨国房地产特许经营商，总部位于得克萨斯州奥斯汀。截至2022年，按销售额计算，它是美国规模最大的房地产特许经营机构，业务覆盖全球多个地区。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CTO vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.7倍
$41.2M
营收增速更快
RIGL
高出6.2%
15.0%
净利率更高
RIGL
高出369.0%
15.1%
两年增速更快
RIGL
近两年复合增速
19.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.2M | $69.8M |
| 净利润 | $6.2M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 175.0% | 33.2% |
| 净利率 | 15.1% | 384.0% |
| 营收同比 | 15.0% | 21.2% |
| 净利润同比 | 174.4% | 1769.2% |
| 每股收益（稀释后） | $0.13 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTORIGL
| Q1 26 | $41.2M | — | ||
| Q4 25 | $38.3M | $69.8M | ||
| Q3 25 | $37.8M | $69.5M | ||
| Q2 25 | $37.6M | $101.7M | ||
| Q1 25 | $35.8M | $53.3M | ||
| Q4 24 | $35.7M | $57.6M | ||
| Q3 24 | $31.8M | $55.3M | ||
| Q2 24 | $28.8M | $36.8M |
净利润CTORIGL
| Q1 26 | $6.2M | — | ||
| Q4 25 | $28.3M | $268.1M | ||
| Q3 25 | $2.9M | $27.9M | ||
| Q2 25 | $-23.4M | $59.6M | ||
| Q1 25 | $2.3M | $11.4M | ||
| Q4 24 | $-15.2M | $14.3M | ||
| Q3 24 | $6.2M | $12.4M | ||
| Q2 24 | $1.2M | $-1.0M |
毛利率CTORIGL
| Q1 26 | — | — | ||
| Q4 25 | 75.0% | 91.5% | ||
| Q3 25 | 75.4% | 93.2% | ||
| Q2 25 | 73.0% | 95.6% | ||
| Q1 25 | 75.2% | 91.7% | ||
| Q4 24 | 74.4% | 89.9% | ||
| Q3 24 | 74.4% | 85.5% | ||
| Q2 24 | 71.1% | 92.4% |
营业利润率CTORIGL
| Q1 26 | 175.0% | — | ||
| Q4 25 | 75.1% | 33.2% | ||
| Q3 25 | 26.6% | 40.9% | ||
| Q2 25 | -33.7% | 60.1% | ||
| Q1 25 | 22.0% | 23.9% | ||
| Q4 24 | -20.4% | 28.9% | ||
| Q3 24 | 15.6% | 25.4% | ||
| Q2 24 | 18.8% | 1.2% |
净利率CTORIGL
| Q1 26 | 15.1% | — | ||
| Q4 25 | 73.9% | 384.0% | ||
| Q3 25 | 7.7% | 40.2% | ||
| Q2 25 | -62.2% | 58.6% | ||
| Q1 25 | 6.3% | 21.5% | ||
| Q4 24 | -42.6% | 24.9% | ||
| Q3 24 | 19.6% | 22.5% | ||
| Q2 24 | 4.1% | -2.8% |
每股收益（稀释后）CTORIGL
| Q1 26 | $0.13 | — | ||
| Q4 25 | $0.81 | $14.11 | ||
| Q3 25 | $0.03 | $1.46 | ||
| Q2 25 | $-0.77 | $3.28 | ||
| Q1 25 | $0.01 | $0.63 | ||
| Q4 24 | $-0.69 | $0.82 | ||
| Q3 24 | $0.17 | $0.70 | ||
| Q2 24 | $-0.03 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $575.4M | $391.5M |
| 总资产 | $1.3B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CTORIGL
| Q1 26 | $8.3M | — | ||
| Q4 25 | $6.5M | $155.0M | ||
| Q3 25 | $9.3M | $137.1M | ||
| Q2 25 | $8.6M | $108.4M | ||
| Q1 25 | $8.4M | $77.1M | ||
| Q4 24 | $9.0M | $77.3M | ||
| Q3 24 | $8.2M | $61.1M | ||
| Q2 24 | $4.8M | $49.1M |
总债务CTORIGL
| Q1 26 | — | — | ||
| Q4 25 | $616.3M | $52.5M | ||
| Q3 25 | $604.2M | $60.0M | ||
| Q2 25 | $605.4M | $60.0M | ||
| Q1 25 | $602.2M | $60.0M | ||
| Q4 24 | $519.0M | $60.0M | ||
| Q3 24 | $526.8M | $60.0M | ||
| Q2 24 | $482.7M | $60.0M |
股东权益CTORIGL
| Q1 26 | $575.4M | — | ||
| Q4 25 | $567.3M | $391.5M | ||
| Q3 25 | $557.3M | $117.6M | ||
| Q2 25 | $574.1M | $81.9M | ||
| Q1 25 | $593.9M | $18.6M | ||
| Q4 24 | $612.8M | $3.3M | ||
| Q3 24 | $595.8M | $-14.6M | ||
| Q2 24 | $491.8M | $-29.9M |
总资产CTORIGL
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $513.6M | ||
| Q3 25 | $1.2B | $242.5M | ||
| Q2 25 | $1.2B | $206.7M | ||
| Q1 25 | $1.2B | $176.0M | ||
| Q4 24 | $1.2B | $164.0M | ||
| Q3 24 | $1.2B | $139.4M | ||
| Q2 24 | $1.0B | $128.4M |
负债/权益比CTORIGL
| Q1 26 | — | — | ||
| Q4 25 | 1.09× | 0.13× | ||
| Q3 25 | 1.08× | 0.51× | ||
| Q2 25 | 1.05× | 0.73× | ||
| Q1 25 | 1.01× | 3.23× | ||
| Q4 24 | 0.85× | 18.25× | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.98× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CTORIGL
| Q1 26 | — | — | ||
| Q4 25 | $64.6M | $22.0M | ||
| Q3 25 | $25.5M | $24.0M | ||
| Q2 25 | $21.9M | $30.5M | ||
| Q1 25 | $10.3M | $-893.0K | ||
| Q4 24 | $59.9M | $14.5M | ||
| Q3 24 | $21.2M | $21.7M | ||
| Q2 24 | $12.9M | $302.0K |
现金转化率CTORIGL
| Q1 26 | — | — | ||
| Q4 25 | 2.28× | 0.08× | ||
| Q3 25 | 8.75× | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | 4.56× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | 3.40× | 1.75× | ||
| Q2 24 | 10.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
